Literature DB >> 3490167

Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy.

G Hermann, J Goldblatt, R N Levy, S J Goldsmith, R J Desnick, G A Grabowski.   

Abstract

The effectiveness of CT and technetium-99m sulfur colloid (99mTc SC) bone-marrow scans in determining the extent and severity of skeletal involvement in 23 patients with type 1 Gaucher's disease was compared with the effectiveness of conventional radiographic techniques and technetium-99m methylene diphosphonate (99mTc MDP) bone scintigrams. Density measurements obtained by CT proved sensitive in differentiating normal marrow (-50 to -120 H). Scintigrams with the sulfur colloid nuclide demonstrated three distinct patterns of uptake: peripheral expansion of normal marrow (profile B), greater marrow expansion with patchy areas lacking uptake (profile C), and greater loss of uptake with retention of the nuclide in other reticuloendothelial organs and circulation (profile D). CT scans provided greater sensitivity in resolving the extent of marrow involvement in affected areas, while the 99mTc SC scintigrams were more effective in overall assessment of the severity of bone-marrow involvement. Both conventional radiographic techniques and 99mTc MDP bone scans were useful primarily as screening procedures or for evaluating specific involved areas. 99mTc MDP scans were useful in evaluating regional defects (i.e., ischemic necrosis) in certain cases, but no consistent patterns were observed. CT and 99mTc SC scans are useful for determining the extent and severity of Gaucher's disease involvement of bone marrow.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490167     DOI: 10.2214/ajr.147.5.943

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

Review 1.  Radiological aspects of Gaucher disease.

Authors:  Robert Katz; Tom Booth; Rikin Hargunani; Peter Wylie; Brian Holloway
Journal:  Skeletal Radiol       Date:  2010-07-25       Impact factor: 2.199

2.  Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.

Authors:  G Ciana; R Addobbati; G Tamaro; A Leopaldi; M Nevyjel; L Ronfani; L Vidoni; M G Pittis; B Bembi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Authors:  Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

Review 4.  Current issues in enzyme therapy for Gaucher disease.

Authors:  G A Grabowski
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

5.  Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.

Authors:  Yuliya Afinogenova; Jiapeng Ruan; Ruhua Yang; Nathaniel Kleytman; Gregory Pastores; Andrew Lischuk; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2019-07-23       Impact factor: 4.797

Review 6.  Imaging of Gaucher disease.

Authors:  William L Simpson; George Hermann; Manisha Balwani
Journal:  World J Radiol       Date:  2014-09-28

Review 7.  Subchondral avascular necrosis: a common cause of arthritis.

Authors:  P G Bullough; E F DiCarlo
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

Review 8.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

9.  MR imaging in adults with Gaucher disease type I: evaluation of marrow involvement and disease activity.

Authors:  G Hermann; R S Shapiro; I F Abdelwahab; G Grabowski
Journal:  Skeletal Radiol       Date:  1993       Impact factor: 2.199

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.